Brief: Cognition Therapeutics Study Of Zervimesine (CT1812) In Early Alzheimer’s Disease Surpasses 50% Enrollment Target
01/07/2025 12:32
July 1 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET COGNITION THERAPEUTICS INC - PHASE 2 SHINE STUDY SHOWS 38% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE COGNITION THERAPEUTICS INC - LOWER P-TAU217 LEVELS SHOW 95% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE COGNITION THERAPEUTICS INC - START STUDY RECEIVES $81 MILLION GRANT SUPPORT FROM NIA Source text: ID:nGNX6Nq37 Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB